Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/
Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor)
These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the patented technology, it is expected to have a ripple effect on markets worth over $100 billion for finished goods and over $10 billion for packages in the lighting, automotive, and IT sectors.
Philips Lighting brand (currently Signify Group) is the world’s leading lighting company with 2023 annual revenue of approximately $7 billion. The Court ordered Conrad Electronic, the global distributor where these products are sold, to immediately cease the sale of certain products manufactured by affiliates of Philips Lighting brand, and also ordered the recall and destruction of infringing products distributed in the market since March 29, 2017. Additionally, the Court ruled that a fine of up to €250,000 per violation would be imposed for each non-compliance. This serves as a strong punitive measure to prevent the recurrence of such infringement activities. These court orders are applicable to all products with a CRI of 70 or higher, not just those manufactured by the affiliates of Philips Lighting brand. Particularly, by defeating the invalidation lawsuit filed by Philips Lighting, Seoul Semiconductor has strengthened the related patent technology.
For the past 30 years, Seoul Semiconductor has been pursuing its vision of "clean, healthy, and beautiful with light," striving to shift the paradigm from harmful artificial lighting to the light of nature. To achieve this, the company invests nearly $100 million annually, about 10% of its revenue, in research and development (R&D). As a result, Seoul Semiconductor holds an overwhelming number of over 18,000 optoelectronic patents in the LED industry and has collaborated with Mitsubishi Chemical Corporation (MCC) for years on joint research and development to improve CRI.
Chung Hoon Lee, Seoul’s founder and CEO said, “Infringement of intellectual property causes frustration among young entrepreneurs and innovative companies.” He added, “Our investment in preventing technology theft helps to create a fairer market and encourages young people and companies around the world to continue innovating, helping all of us contribute to a better world. This aligns with one of our company's three core missions: honor, trust, and contribution.”
About Seoul Semiconductor
Seoul Semiconductor is the world's third-largest global opto semiconductor (LED) company that has focused solely on LEDs for the past 30 years. Under the vision of "Make the world clean, healthy and beautiful with light" Seoul Semiconductor leads the new paradigm of light with world-first technologies in the fields of lighting, automotive, and IT (backlighting), while Seoul Viosys, a subsidiary, is at the forefront of MicroLED, UV, sensors, and Dacom.
Notable world-first technologies include the innovative no-wire LED "WICOP"; "SunLike," which replicates the full spectrum of natural sunlight; the high-voltage LED "Acrich"; the ultra-bright "nPola" LED, which is more than 10 times brighter than traditional LEDs; the RGB one-chip MicroLED "WICOP Pixel"; and the UV cleaning technology "Violeds."
Seoul Semiconductor holds an overwhelming 18,000 patents in the industry and has won over 100 patent litigations across eight countries in the past 20 years. Believing that the patent system offers hope to young people and serves as a stepping stone to a better world, the company actively engages in intellectual property protection activities. For more details, please visit our official websites (http://www.seoulsemicon.com/en, https://www.seoulviosys.com/en) and social media channels (LinkedIn).
About CRI (Color Rendering Index)
An indicator of how accurately a light source reproduces the colors of objects under natural sunlight. (For example, CRI 70: Designed so that the colors of 14 standard color samples match more than 70% of the colors seen under sunlight.)
View source version on businesswire.com: https://www.businesswire.com/news/home/20241225151382/en/
Contacts
Seoul Semiconductor Co., Ltd.
Jinseop Jung
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Second Consecutive Year15.5.2025 07:01:00 EEST | Press release
Corona has been recognized as the most valuable beer brand in the world for the second consecutive year in Kantar's BrandZ 2025 Most Valuable Global Brands report, released today. Eight out of the 10 most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the top brands in the world. In 2024 AB InBev produced all-time high revenue and 15% Underlying EPS growth. The year marked double-digit growth for Corona outside of its home market of Mexico and triple-digit growth of its no-alcohol brand Corona Cero. Corona Cero is the first beer brand to sponsor the Olympic Games making its debut in Paris 2024. In 2025, Corona is celebrating its 100-year anniversary with events all over the world through its “Corona 100” platform. Corona is followed by Budweiser, the second most valuable beer brand in the world. Michelob ULTRA moved up one spot to #5 amongst beer brands globally. Michelob ULTRA has also been named the winner
Forrester Opens Nominations For Its 2025 B2B Awards In EMEA And APAC15.5.2025 07:00:00 EEST | Press release
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2025 B2B Return On Integration Honors and B2B Programs Of The Year Awards in Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA). These awards will recognize B2B organizations based in both regions for achieving functional excellence and outstanding alignment across marketing, sales, and product — the B2B revenue engine — to improve customer experience and drive growth. Nominations for both award categories are open to organizations of all sizes in each region. B2B leaders across APAC and EMEA — including chief marketing officers, chief sales officers, chief product officers, and other marketing, sales, and product leaders — are invited and encouraged to apply. To be eligible, programs need to be developed by leaders and teams based in the APAC or EMEA regions. The nomination criteria for the two awards are as follows: B2B Return On Integration (ROI) Honors. These awards showcase organizations that have achi
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom